SCHEMBL29974385

SCHEMBL29974385

O=C(O)c1cc2c(Cl)cc(F)cc2[nH]1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 3/20 0.70
RHEB Q15382 6/20 0.62
EIF4A3 P38919 3/20 0.60
HPGD P15428 3/20 0.51
KDM4E B2RXH2 2/20 0.51
LMNA P02545 2/20 0.51
TSHR P16473 2/20 0.51
CYP2C19 P33261 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
PDPK1 O15530 1/20 0.51
ALDH1A1 P00352 1/20 0.51
NFKB1 P19838 1/20 0.51
APEX1 P27695 1/20 0.51
HSD17B10 Q99714 1/20 0.51
MEN1 O00255 2/20 0.47
CYP2C9 P11712 2/20 0.47
BLM P54132 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPK1 P28482 1/20 0.47
GRIN2D O15399 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15515831 1.00 GRIN1 (0.70) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL29063125 0.85 GRIN1 (0.50) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL1144892 0.84 EIF4A3 (0.63) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL29655546 0.84 EIF4A3 (0.63) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL727389 0.82 GRIN1 (1.00) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL29531428 0.82 GRIN1 (1.00) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL24020677 0.81 ULK1 (0.47) GRIN1RHEBEIF4A3MEN1KMT2A
SCHEMBL30310352 0.81 ULK1 (0.47) GRIN1RHEBEIF4A3MEN1KMT2A
SCHEMBL21624049 0.79 KDM4E (0.51) GRIN1RHEBEIF4A3HPGDKDM4E
SCHEMBL20505503 0.79 EIF4A3 (0.54) GRIN1RHEBEIF4A3HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3976617-B1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2025-04-23 EP disclosed
US-20220348592-A1 FUSED HETEROCYCLIC DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2022-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348592-A1 FUSED HETEROCYCLIC DERIVATIVES HAVCR2, HCCS, GOT2 GRIN1 3749/4885RHEB 1262/4885EIF4A3 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.